Immunological investigations · 2026
Unleashing the Potential of Anti-CD45RB Antibodies in Transplantation.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yanling, Li Nan, Li Yachao
Аннотация
BACKGROUND: Organ transplantation faces challenges of chronic rejection and infection due to immunosuppression. Inducing long-term immune tolerance is a key goal, with anti-CD45RB antibody being a studied target for decades.
METHODS: This review examines its mechanisms-modulating T cells (e.g.promoting Tregs), B cells, and cytokines-and efficacy across transplantation models (e.g.pancreatic, cardiac, cutaneous), including combination therapies.
CONCLUSIONS: Efficacy varies by model: monotherapy induced tolerance in certain islet transplants but not skin grafts. Combination with agents like anti-CD40L or rapamycin significantly prolonged graft survival (e.g.to 100% in heart transplants). Dosage, timing, and recipient immune status influence outcomes, with Treg involvement as a common mechanism.
FUTURE DIRECTIONS: Further research should explore synergies with clinical immunosuppressants and mechanisms in large animal xenografts to advance clinical translation.
METHODS: This review examines its mechanisms-modulating T cells (e.g.promoting Tregs), B cells, and cytokines-and efficacy across transplantation models (e.g.pancreatic, cardiac, cutaneous), including combination therapies.
CONCLUSIONS: Efficacy varies by model: monotherapy induced tolerance in certain islet transplants but not skin grafts. Combination with agents like anti-CD40L or rapamycin significantly prolonged graft survival (e.g.to 100% in heart transplants). Dosage, timing, and recipient immune status influence outcomes, with Treg involvement as a common mechanism.
FUTURE DIRECTIONS: Further research should explore synergies with clinical immunosuppressants and mechanisms in large animal xenografts to advance clinical translation.